With the help of a $2.3 million grant, Purdue University animal science professor Shihuan Kuang’s research will continue in an effort to better understand the origin and function of these newly-discovered stem cells.
Cancer-fighting nuclear medicine firms find home in central Indiana
Indianapolis’ newest publicly company, Point Biopharma Inc., is the latest player in a field expected to see explosive growth as doctors and researchers look for new ways to shrink tumors.Read More
2020 Innovation Issue: Brothers share a knack for creating life sciences companies
Philip and Martin Low’s latest venture, Eradivir, was incorporated in February to develop a treatment that would fight the influenza virus, but COVID-19 prompted a tweak to the business plan.Read More
Ossium Health wants to build a huge bank of bone marrow and stem cells from deceased organ donors to treat patient with blood cancers and to improve organ transplantations.
A startup that’s planning to launch a $60 million drug-manufacturing plant sees big growth in contract manufacturing.
The medical school said it is testing the use of tezampanel, an experimental drug for migraines developed by Indianapolis-based drugmaker Eli Lilly and Co., to treat opioid withdrawal syndrome and other addictions and mental illnesses.
Some of the vaccine trials in the United States are taking place at Indiana University School of Medicine in Indianapolis.
The grant will help fund an ongoing study to evaluate long-term health outcomes for cancer patients who receive life-saving chemotherapy treatments that often have difficult side effects.
Under the agreement, researchers will study patients who used Lilly autoimmune therapies that are under consideration for the treatment of other autoimmune diseases, including inflammatory bowel disease and psoriasis.
West Lafayette-based Bioanalytical Systems’ latest executive departure comes amid recent signs of stability, turnaround and growth for a company that just three years ago was on the verge of sinking.
The International Council of Motorsport Sciences, established in Indianapolis in 1988, will relocate from Texas later this month after hiring veteran motorsports exec Tom Weisenbach as its new executive director.
Development Corp., is helping raise money for a women-focused cancer research initiative. The campaign, which will run through June, is in its second year.
For companies that pursue technological advances and innovative solutions, bias can have an enduring impact, making it easy for the cycle to be perpetuated.
Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories.
The not-for-profit and its health research are a testament to the idea that all innovation is related—even when the connection appears tenuous at first glance.
The emerging health care field seeks to develop methods for replacing or reinvigorating damaged human organs, cells and tissues.
The Indianapolis-based drugmaker said it will combine its capability for quickly developing antibodies with AbCellera’s “rapid pandemic response platform,” with the goal of getting a treatment into clinics for human testing within four months.
Dr. Christopher Stobart and his students are focusing on an enzyme in the virus that could inhibit its replication, and plan to submit the findings to a virology journal in coming months.
Patient data is increasingly in the hands of for-profit industries. Insurance firms and other for-profit companies have been collecting patient data that yields important information that could be used to shape medical care and health policy.
Mucus may be gross, but we produce a lot of it. And new research is uncovering just how beneficial it is in the human body.
The spinoff, called Sexton Biotechnologies, has raised $5 million in outside investment and will spin off in October. The biotech develops cell and gene therapy tools used to grow cells for medical purposes.